DCGI approves trials for Bharat Biotech's nasal Covid booster in India

The Drugs Controller General of India approves trials of Bharat Biotech's intranasal Covid booster dose in India. The trial will be done on 900 subjects. The DCGI's Subject Expert Committee (SEC) gave an ‘in-principle' approval to Bharat Biotech for the 'phase-III booster dose study' for its intranasal Covid vaccine, a first of its kind in India, and asked it to submit protocols for approval 3 weeks ago.